Dr. Robert G. Perry, M.D
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 27
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 276
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
FL license ME94381
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Regional Hospital Hollywood, FL
- Memorial Hospital West Pembroke Pines, FL
- Memorial Hospital Miramar Miramar, FL
- Memorial Hospital Pembroke Pembroke Pines, FL
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 276
- Services billed
- 822
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 454 | 216 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 131 | 131 |
| Established patient office or other outpatient visit, 20-29 minutes | 31 | 29 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 24 | 21 |
| Established patient office or other outpatient visit, 40-54 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 28 payments worth $664 in total to this clinician.
| Novo Nordisk Inc | $169 |
|---|---|
| Lilly USA, LLC | $102 |
| Regeneron Healthcare Solutions, Inc. | $68.86 |
| AbbVie Inc. | $66.88 |
| Verity Pharmaceuticals Inc. | $46.79 |
| Pfizer Inc. | $43.43 |
| AstraZeneca Pharmaceuticals LP | $39.52 |
| Axsome Therapeutics, Inc. | $27.98 |
| Food and Beverage | $664 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 26 industry-funded studies in 2025, from 14 companies. The companies reported $3,335,091 in research payments for these studies, mostly to the institutions running them.
- An Open-Label Single-Dose Study to Evaluate the Pharmacokinetics of AMG 133 in Participants with Varying Degrees of Hepatic Impairment
Amgen Inc. - A Phase 1, Multicenter, Open-label, Single -dose Study to Assess the Pharmacokinetics of Repotrectinib in Healthy Participants and those with Moderate, and Severe Hepatic Impairment
E.r. Squibb & Sons, L.l.c. - CPET
Genentech, Inc. - A Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD2389 CAMPOLINA
AstraZeneca UK Limited - A Phase I Multicentre Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD5004
AstraZeneca Ab - A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics Safety and Tolerability of AZD5004
AstraZeneca Ab - A Phase I Multicentre Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD5004
AstraZeneca UK Limited - Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presume…
Boehringer Ingelheim International GmbH - A Phase 1, open-label study to investigate the pharmacokinetics and safety of remibrutinib (LOU064) in participants with severe renal impairment compared to matched healthy participants with normal renal function
Novartis Pharmaceuticals Corporation - A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Pharmacokinetics of ITI-1284 in Subjects with Normal and Impaired Hepatic Function
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.)
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.